Ewa Lange
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ewa Lange has a total of 81 co-authors. Here are the top co-authors by number of shared publications:
- Danuta Gajewska
Department of Dietetics, Institute of Human Nutrition Sciences, Warsaw University of Life Sciences (WULS), 159C Nowoursynowska Str., 02-776 Warsaw, Poland
5 shared publications - Dominika Głąbska
Department of Dietetics, Institute of Human Nutrition Sciences, Warsaw University of Life Sciences (SGGW-WULS), 159c Nowoursynowska Street, 02-776 Warsaw, Poland
5 shared publications - Paulina Katarzyna Kęszycka
Department of Dietetics, Institute of Human Nutrition Sciences, Warsaw University of Life Sciences (SGGW-WULS), 159 C Nowoursynowska Street, 02-776 Warsaw, Poland
5 shared publications - Dominika Guzek
Department of Food Market and Consumer Research, Institute of Human Nutrition Sciences, Warsaw University of Life Sciences (SGGW-WULS), 159C Nowoursynowska Street, 02-776 Warsaw, Poland
4 shared publications - Ewelina Pałkowska-Goździk
Department of Dietetics, Institute of Human Nutrition Sciences, Warsaw University of Life Sciences (SGGW-WULS), 159 C Nowoursynowska Street, 02-776 Warsaw, Poland
4 shared publications - Anna Harton
Department of Dietetics, Institute of Human Nutrition Sciences, Warsaw University of Life Sciences (WULS), 159C Nowoursynowska St, 02-776 Warsaw, Poland
3 shared publications
Latest Publications
- Open Access
- 2 October 2026
- Published by Wroclaw Medical University in Advances in Clinical and Experimental Medicine
- Vol. 35 (11)
Diet and nutrition in obesity treated with incretin-based therapies: A scientific statement of the Polish Society of Dietetics
- 2 October 2026
- Published by Wroclaw Medical University in Advances in Clinical and Experimental Medicine
- Vol. 35 (11)
Open AccessDiet and nutrition in obesity treated with incretin-based therapies: A scientific statement of the Polish Society of Dietetics
- Open Access
Effect of Inulin-Type Fructans on Body Composition, Carbohydrate Metabolism and Energy Expenditure in Patients with Psoriasis: Results of INGUTSKIN Randomized Controlled Trial
Introduction: Patients with psoriasis, a non-contagious, chronic, systemic inflammatory skin disease, often suffer from carbohydrate metabolism disorders, which can exacerbate systemic inflammation. Methods: This randomized, double-blind, placebo-controlled trial (RCT) evaluated the effects of chicory-derived inulin-type fructans (ITFs) on body composition, energy expenditure, and carbohydrate metabolism in patients with mild psoriasis (PS), using a healthy control (n = 32) group as a baseline reference. PS participants (n = 56) were randomized to receive 15 g/day of ITFs (n = 29) or a placebo (n = 27) for 8 weeks. Body composition using bioelectrical impedance analysis (BIA), carbohydrate metabolism (fasting glucose, insulin, glycated hemoglobin, Oral Glucose Tolerance Test (OGTT)) and resting energy expenditure (resting metabolic rate (RMR), oxygen consumption (VO2), carbon dioxide production (VCO2)) via indirect calorimetry were determined. Results: At baseline, patients with PS had significantly (p < 0.01) higher body mass index and visceral fat levels, and abnormal levels of selected parameters of carbohydrate metabolism, compared with healthy controls. Following the intervention, the ITFs group maintained stable fasting glucose levels, while the placebo group showed an undesirable increase (Δglucose = +5.7 mg/dL; p < 0.01). The energy expenditure analysis revealed a significant treatment effect on RMR and VO2 parameters (p < 0.01), with a decrease in the placebo group (p < 0.01) while remaining stable in the prebiotic group. There was no significant effect of the intervention on body composition and anthropometric parameters. Conclusions: Patients with PS exhibit a higher metabolic risk than healthy controls. Although no significant changes were observed within the intervention groups, the deterioration of metabolic indices in the placebo group may indicate an unfavorable effect of the maltodextrin. Consequently, the stabilization of parameters in the prebiotic group should be interpreted with great caution. This RCT was registered at ClinicalTrials.gov (NCT05971992).
Open AccessEffect of Inulin-Type Fructans on Body Composition, Carbohydrate Metabolism and Energy Expenditure in Patients with Psoriasis: Results of INGUTSKIN Randomized Controlled Trial
Introduction: Patients with psoriasis, a non-contagious, chronic, systemic inflammatory skin disease, often suffer from carbohydrate metabolism disorders, which can exacerbate systemic inflammation. Methods: This randomized, double-blind, placebo-controlled trial (RCT) evaluated the effects of chicory-derived inulin-type fructans (ITFs) on body composition, energy expenditure, and carbohydrate metabolism in patients with mild psoriasis (PS), using a healthy control (n = 32) group as a baseline reference. PS participants (n = 56) were randomized to receive 15 g/day of ITFs (n = 29) or a placebo (n = 27) for 8 weeks. Body composition using bioelectrical impedance analysis (BIA), carbohydrate metabolism (fasting glucose, insulin, glycated hemoglobin, Oral Glucose Tolerance Test (OGTT)) and resting energy expenditure (resting metabolic rate (RMR), oxygen consumption (VO2), carbon dioxide production (VCO2)) via indirect calorimetry were determined. Results: At baseline, patients with PS had significantly (p < 0.01) higher body mass index and visceral fat levels, and abnormal levels of selected parameters of carbohydrate metabolism, compared with healthy controls. Following the intervention, the ITFs group maintained stable fasting glucose levels, while the placebo group showed an undesirable increase (Δglucose = +5.7 mg/dL; p < 0.01). The energy expenditure analysis revealed a significant treatment effect on RMR and VO2 parameters (p < 0.01), with a decrease in the placebo group (p < 0.01) while remaining stable in the prebiotic group. There was no significant effect of the intervention on body composition and anthropometric parameters. Conclusions: Patients with PS exhibit a higher metabolic risk than healthy controls. Although no significant changes were observed within the intervention groups, the deterioration of metabolic indices in the placebo group may indicate an unfavorable effect of the maltodextrin. Consequently, the stabilization of parameters in the prebiotic group should be interpreted with great caution. This RCT was registered at ClinicalTrials.gov (NCT05971992).
- Open Access
- 20 May 2026
- Published by Institute of Rural Health in Medycyna Ogólna i Nauki o Zdrowiu
Ocena rozpowszechnienia zachowań ortorektycznych wśród wybranych grup młodych kobiet
- 20 May 2026
- Published by Institute of Rural Health in Medycyna Ogólna i Nauki o Zdrowiu
Open AccessOcena rozpowszechnienia zachowań ortorektycznych wśród wybranych grup młodych kobiet
- Open Access
The Effect of a Low-Energy and Low-Glycemic Diet on Adipose Tissue Metabolism and Energy Expenditure in Women with Excess Body Weight
Background/Objectives: Data indicate that a low-glycemic index diet may be an effective nutritional approach to improve cardiometabolic parameters and support weight loss in obese individuals. The purpose of the study was to evaluate and compare the effects of a free-choice low-GI diet and a low-energy diet in women with excessive body weight on the value of anthropometric parameters, selected indices of lipid, carbohydrate, and fat tissue metabolism, and alterations in resting metabolic rate (RMR). Methods: Forty-six women were randomly assigned to either a low-GI diet (LGI) or a low-energy diet (LED) for 12 weeks. Dietary habits and anthropometric parameters (waist circumference, body weight, fat mass, total body water, and fat-free mass) were monitored and reviewed regularly. Biochemical parameters—including lipid profile, markers of glucose metabolism, adiponectin, leptin, glucagon-like peptide-1 (GLP-1), and RMR—were assessed at baseline and after three months of dietary intervention. Results: Both diets had a beneficial effect on monitored parameters; however, the LGI diet was shown to be superior in reducing waist circumference, LDL, non-HDL cholesterol, leptin, and HbA1c, and in increasing GLP-1 levels without decline in RMR. Conclusions: A low-GI diet, under dietary supervision, can improve metabolic performance and promote weight reduction in people with obesity.
Open AccessThe Effect of a Low-Energy and Low-Glycemic Diet on Adipose Tissue Metabolism and Energy Expenditure in Women with Excess Body Weight
Background/Objectives: Data indicate that a low-glycemic index diet may be an effective nutritional approach to improve cardiometabolic parameters and support weight loss in obese individuals. The purpose of the study was to evaluate and compare the effects of a free-choice low-GI diet and a low-energy diet in women with excessive body weight on the value of anthropometric parameters, selected indices of lipid, carbohydrate, and fat tissue metabolism, and alterations in resting metabolic rate (RMR). Methods: Forty-six women were randomly assigned to either a low-GI diet (LGI) or a low-energy diet (LED) for 12 weeks. Dietary habits and anthropometric parameters (waist circumference, body weight, fat mass, total body water, and fat-free mass) were monitored and reviewed regularly. Biochemical parameters—including lipid profile, markers of glucose metabolism, adiponectin, leptin, glucagon-like peptide-1 (GLP-1), and RMR—were assessed at baseline and after three months of dietary intervention. Results: Both diets had a beneficial effect on monitored parameters; however, the LGI diet was shown to be superior in reducing waist circumference, LDL, non-HDL cholesterol, leptin, and HbA1c, and in increasing GLP-1 levels without decline in RMR. Conclusions: A low-GI diet, under dietary supervision, can improve metabolic performance and promote weight reduction in people with obesity.
- Open Access
Efficacy of a Low-FODMAP Diet on the Severity of Gastrointestinal Symptoms and Quality of Life in the Treatment of Gastrointestinal Disorders—A Systematic Review of Randomized Controlled Trials
Background: A low-FODMAP diet is considered as a potential supportive treatment approach in some gastrointestinal disorders. The aim of this study was to systematically review the literature for randomized controlled trials assessing the efficacy of the low-FODMAP diet on the severity of gastrointestinal symptoms and quality of life in patients with gastrointestinal disorders. Methods: This review was conducted in accordance with CASP tool and PRISMA guidelines. A comprehensive search of the PubMed, Scopus, and Web of Science databases resulted in the identification of fourteen randomized controlled trials. Results: Ten studies examined the effect of the low-FODMAP diet in patients with irritable bowel syndrome (IBS), three with inflammatory bowel disease (IBD), and one with symptomatic proton pump inhibitor (PPI) refractory gastroesophageal reflux disease (GERD). All interventions compared the low-FODMAP diet with another diet and lasted from 3 to 12 weeks. Most studies on IBS showed significant improvements in abdominal pain, bloating, and quality of life compared to control diets. In IBD, improvements were mainly observed in functional gastrointestinal symptoms, while no clear benefit was demonstrated in GERD. Heterogeneity in study designs, intervention durations, comparator diets, and outcome measures limited the ability to conduct a meta-analysis. Conclusions: Although a low-FODMAP diet may reduce symptoms in selected individuals, it is not universally necessary. Importantly, the diet’s restrictive nature and potential long-term effects—such as nutritional deficiencies and alterations in gut microbiota—highlight the need for clinical supervision by dietitians with expertise in gastrointestinal disorders. Furthermore, in some cases, symptom improvement may be achievable through less restrictive changes, such as improving food hygiene and reducing intake of processed or high-sugar foods. Further high-quality randomized controlled trials with standardized endpoints and longer follow-up are needed to clarify the efficacy and safety of the low-FODMAP diet across various gastrointestinal conditions.
Open AccessEfficacy of a Low-FODMAP Diet on the Severity of Gastrointestinal Symptoms and Quality of Life in the Treatment of Gastrointestinal Disorders—A Systematic Review of Randomized Controlled Trials
Background: A low-FODMAP diet is considered as a potential supportive treatment approach in some gastrointestinal disorders. The aim of this study was to systematically review the literature for randomized controlled trials assessing the efficacy of the low-FODMAP diet on the severity of gastrointestinal symptoms and quality of life in patients with gastrointestinal disorders. Methods: This review was conducted in accordance with CASP tool and PRISMA guidelines. A comprehensive search of the PubMed, Scopus, and Web of Science databases resulted in the identification of fourteen randomized controlled trials. Results: Ten studies examined the effect of the low-FODMAP diet in patients with irritable bowel syndrome (IBS), three with inflammatory bowel disease (IBD), and one with symptomatic proton pump inhibitor (PPI) refractory gastroesophageal reflux disease (GERD). All interventions compared the low-FODMAP diet with another diet and lasted from 3 to 12 weeks. Most studies on IBS showed significant improvements in abdominal pain, bloating, and quality of life compared to control diets. In IBD, improvements were mainly observed in functional gastrointestinal symptoms, while no clear benefit was demonstrated in GERD. Heterogeneity in study designs, intervention durations, comparator diets, and outcome measures limited the ability to conduct a meta-analysis. Conclusions: Although a low-FODMAP diet may reduce symptoms in selected individuals, it is not universally necessary. Importantly, the diet’s restrictive nature and potential long-term effects—such as nutritional deficiencies and alterations in gut microbiota—highlight the need for clinical supervision by dietitians with expertise in gastrointestinal disorders. Furthermore, in some cases, symptom improvement may be achievable through less restrictive changes, such as improving food hygiene and reducing intake of processed or high-sugar foods. Further high-quality randomized controlled trials with standardized endpoints and longer follow-up are needed to clarify the efficacy and safety of the low-FODMAP diet across various gastrointestinal conditions.
- Open Access
- 19 December 2024
- Published by MDPI AG in Applied Sciences
- Vol. 14 (24) , 11900
The Influence of Various Types of Functional Bread on Postprandial Glycemia in Healthy Adults
Bread is a crucial component of a balanced diet. Increasing the choice of functional bakery products based on whole grain flours, with the addition of seeds and grains, can improve health, including reducing postprandial glycemia and the risk of metabolic syndrome. The current study attempted to characterize the relationship between the composition and nutritional value of 23 different types of functional bread and postprandial glycemic response values. This study involved 209 non-obese healthy volunteers aged between 18 and 50. The study protocol followed the standard glycemic index (GI) method outlined by the International Standard, ISO 26642:2010. Most of the examined bread had a low GI and was composed mainly of rye, oats, buckwheat flour with a sourdough starter, and oilseeds. Postprandial glycemia was negatively associated with the fat, protein, and fiber content of bread. However, the GI depended directly on the carbohydrate content and, inversely, on the fat content in wheat bread and bread containing oilseeds. Similarly, using whole-grain flour and sourdough in a functional bakery reduces the GI. Adding oilseeds and sourdough to bread also reduced blood glucose levels approximately one hour after a meal. A greater number of ingredients in a recipe may be associated with a higher GI. In designing a functional bread with a potentially beneficial effect on postprandial glycemia, the nutritional value, type of fermentation, and additives (type and number) are worth considering. The high variability in postprandial glycemia after bread consumption is related to several factors and requires GI determination according to standard methods to ensure that the information provided to the consumer is reliable.
- 19 December 2024
- Published by MDPI AG in Applied Sciences
- Vol. 14 (24) , 11900
Open AccessThe Influence of Various Types of Functional Bread on Postprandial Glycemia in Healthy Adults
Bread is a crucial component of a balanced diet. Increasing the choice of functional bakery products based on whole grain flours, with the addition of seeds and grains, can improve health, including reducing postprandial glycemia and the risk of metabolic syndrome. The current study attempted to characterize the relationship between the composition and nutritional value of 23 different types of functional bread and postprandial glycemic response values. This study involved 209 non-obese healthy volunteers aged between 18 and 50. The study protocol followed the standard glycemic index (GI) method outlined by the International Standard, ISO 26642:2010. Most of the examined bread had a low GI and was composed mainly of rye, oats, buckwheat flour with a sourdough starter, and oilseeds. Postprandial glycemia was negatively associated with the fat, protein, and fiber content of bread. However, the GI depended directly on the carbohydrate content and, inversely, on the fat content in wheat bread and bread containing oilseeds. Similarly, using whole-grain flour and sourdough in a functional bakery reduces the GI. Adding oilseeds and sourdough to bread also reduced blood glucose levels approximately one hour after a meal. A greater number of ingredients in a recipe may be associated with a higher GI. In designing a functional bread with a potentially beneficial effect on postprandial glycemia, the nutritional value, type of fermentation, and additives (type and number) are worth considering. The high variability in postprandial glycemia after bread consumption is related to several factors and requires GI determination according to standard methods to ensure that the information provided to the consumer is reliable.
- Open Access
Relationship between Bone Mineral Density and Selected Parameters of Calcium-Phosphate Economy with Dietary Management and Metabolic Control in Polish Pediatric Patients with Classical Homocystinuria—A Preliminary Study
Background: Classical homocystinuria (HCU) is an inborn defect of methionine metabolism caused by a deficiency of the enzyme cystathionine β-synthase (CBS). The main symptoms of classical homocystinuria are lens subluxation, bone lesions, vascular disease and developmental delay/intellectual disability. The treatment method for HCU is a methionine-poor diet supplemented with amino acid preparations. The aim of the study was to examine the relationship of dietary factors, metabolic compensation and selected skeletal parameters in patients with HCU. Methods: Bone mineral density measurements (DXA) were performed in pediatric patients with HCU, and blood levels of selected amino acids, minerals and vitamins, as well as dietary nutritional value, were analyzed. Results: A total of 11 patients with HCU whose median age was 9.3 years were enrolled in the study. The median DXA total body less head of HCU patients was −0.4 z-score, and the lumbar spine was −1.4 z-score. Despite supplementation, calcium intake was below the age norm. Average vitamin D3 intake was in line with recommendations, but 36% of patients had reduced blood levels. Bone mineral density depended on blood levels of 25-hydroxyvitamin D, homocysteine and methionine, as well as on BMI, age and intake of natural protein (R2 = 98.5%, p = 0.015; R2 = 86.7%, p = 0.0049) and protein from an amino acid preparation (r = 0.69, p = 0.026). Conclusion: The results of the study indicate the need for regular densitometry in patients with HCU and also the use of additional calcium and vitamin D3 supplementation. It is also necessary to perform a comprehensive analysis of the diet and metabolic controls.
Open AccessRelationship between Bone Mineral Density and Selected Parameters of Calcium-Phosphate Economy with Dietary Management and Metabolic Control in Polish Pediatric Patients with Classical Homocystinuria—A Preliminary Study
Background: Classical homocystinuria (HCU) is an inborn defect of methionine metabolism caused by a deficiency of the enzyme cystathionine β-synthase (CBS). The main symptoms of classical homocystinuria are lens subluxation, bone lesions, vascular disease and developmental delay/intellectual disability. The treatment method for HCU is a methionine-poor diet supplemented with amino acid preparations. The aim of the study was to examine the relationship of dietary factors, metabolic compensation and selected skeletal parameters in patients with HCU. Methods: Bone mineral density measurements (DXA) were performed in pediatric patients with HCU, and blood levels of selected amino acids, minerals and vitamins, as well as dietary nutritional value, were analyzed. Results: A total of 11 patients with HCU whose median age was 9.3 years were enrolled in the study. The median DXA total body less head of HCU patients was −0.4 z-score, and the lumbar spine was −1.4 z-score. Despite supplementation, calcium intake was below the age norm. Average vitamin D3 intake was in line with recommendations, but 36% of patients had reduced blood levels. Bone mineral density depended on blood levels of 25-hydroxyvitamin D, homocysteine and methionine, as well as on BMI, age and intake of natural protein (R2 = 98.5%, p = 0.015; R2 = 86.7%, p = 0.0049) and protein from an amino acid preparation (r = 0.69, p = 0.026). Conclusion: The results of the study indicate the need for regular densitometry in patients with HCU and also the use of additional calcium and vitamin D3 supplementation. It is also necessary to perform a comprehensive analysis of the diet and metabolic controls.
- Open Access
- 25 September 2022
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 19 (19) , 12117
Comparison of Glycemic Response to Carbohydrate Meals without or with a Plant-Based Formula of Kidney Bean Extract, White Mulberry Leaf Extract, and Green Coffee Extract in Individuals with Abdominal Obesity
Due to the rising prevalence of obesity and type 2 diabetes, a strategy that can positively influence diet quality in a simple way is being explored, since a low glycemic index (GI) diet is advised in the dietoprophylaxis and diet therapy of diabetes. Methods: Twenty-three women with abdominal obesity participated in the study. The postprandial glycemic response and glycemic index were determined after three carbohydrate meals (noodle soup, white rice, strawberry sorbet) without or with the addition of a plant-base supplement (extracts of kidney bean, white mulberry leaf, and green coffee) with a potentially hypoglycemic effect. For two products (instant noodle soup and white rice), the addition of the plant supplement resulted in a reduction in glicemic iAUC values (respectively, by: 17.1%, p = 0.005 and 5.3%; p = 0.03; 40.6%, p = 0.004 and 5.3%, p = 0.019). However, this effect was not observed for strawberry sorbet. The blood glucose concentrations 30 min after the consumption of instant noodle soup and white rice with the plant-based formula addition significantly affected the GI value of tested meals (p = 0.0086, r = 0.53; p = 0.0096, r = 0.53), which may indicate the effect of this plant supplement on enterohormone and/or insulin secretion. Conclusion: A formula containing kidney bean, white mulberry leaves, and green coffee extracts may therefore be a notable factor in lowering postprandial glycemia and the GI of carbohydrate foods. However, further research is needed to determine for which food groups and meals its use may be most effective.
- 25 September 2022
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 19 (19) , 12117
Open AccessComparison of Glycemic Response to Carbohydrate Meals without or with a Plant-Based Formula of Kidney Bean Extract, White Mulberry Leaf Extract, and Green Coffee Extract in Individuals with Abdominal Obesity
Due to the rising prevalence of obesity and type 2 diabetes, a strategy that can positively influence diet quality in a simple way is being explored, since a low glycemic index (GI) diet is advised in the dietoprophylaxis and diet therapy of diabetes. Methods: Twenty-three women with abdominal obesity participated in the study. The postprandial glycemic response and glycemic index were determined after three carbohydrate meals (noodle soup, white rice, strawberry sorbet) without or with the addition of a plant-base supplement (extracts of kidney bean, white mulberry leaf, and green coffee) with a potentially hypoglycemic effect. For two products (instant noodle soup and white rice), the addition of the plant supplement resulted in a reduction in glicemic iAUC values (respectively, by: 17.1%, p = 0.005 and 5.3%; p = 0.03; 40.6%, p = 0.004 and 5.3%, p = 0.019). However, this effect was not observed for strawberry sorbet. The blood glucose concentrations 30 min after the consumption of instant noodle soup and white rice with the plant-based formula addition significantly affected the GI value of tested meals (p = 0.0086, r = 0.53; p = 0.0096, r = 0.53), which may indicate the effect of this plant supplement on enterohormone and/or insulin secretion. Conclusion: A formula containing kidney bean, white mulberry leaves, and green coffee extracts may therefore be a notable factor in lowering postprandial glycemia and the GI of carbohydrate foods. However, further research is needed to determine for which food groups and meals its use may be most effective.
- Open Access
Clinical Outcomes after Oat Beta-Glucans Dietary Treatment in Gastritis Patients
The prevalence of gastritis in humans is constantly growing and a prediction of an increase in this health problem is observed in many countries. For this reason, effective dietary therapies are sought that can alleviate the course of this disease. The objective of this study was to determine the effect of chemically pure oat beta-glucan preparations with different molar masses, low or high, used for 30 days in patients with histologically diagnosed chronic gastritis. The study enrolled 48 people of both genders of different ages recruited from 129 patients with a gastritis diagnosis. Before and after the therapy, hematological, biochemical, immunological and redox balance parameters were determined in the blood and the number of lactic acid bacteria and SCFA concentrations in the feces. Our results demonstrated a beneficial effect of oat beta-glucans with high molar mass in chronic gastritis in humans, resulting in reduced mucosal damage and healthy changes in SCFA fecal concentration and peripheral blood serum glutathione metabolism and antioxidant defense parameters. This fraction of a highly purified oat beta-glucan is safe for humans. Its action is effective after 30 days of use, which sheds new light on the nutritional treatment of chronic gastritis.
Open AccessClinical Outcomes after Oat Beta-Glucans Dietary Treatment in Gastritis Patients
The prevalence of gastritis in humans is constantly growing and a prediction of an increase in this health problem is observed in many countries. For this reason, effective dietary therapies are sought that can alleviate the course of this disease. The objective of this study was to determine the effect of chemically pure oat beta-glucan preparations with different molar masses, low or high, used for 30 days in patients with histologically diagnosed chronic gastritis. The study enrolled 48 people of both genders of different ages recruited from 129 patients with a gastritis diagnosis. Before and after the therapy, hematological, biochemical, immunological and redox balance parameters were determined in the blood and the number of lactic acid bacteria and SCFA concentrations in the feces. Our results demonstrated a beneficial effect of oat beta-glucans with high molar mass in chronic gastritis in humans, resulting in reduced mucosal damage and healthy changes in SCFA fecal concentration and peripheral blood serum glutathione metabolism and antioxidant defense parameters. This fraction of a highly purified oat beta-glucan is safe for humans. Its action is effective after 30 days of use, which sheds new light on the nutritional treatment of chronic gastritis.
- Open Access
Effectiveness of Personalized Low Salicylate Diet in the Management of Salicylates Hypersensitive Patients: Interventional Study
Salicylic acid and its derivatives (including acetylsalicylic acid/aspirin) are popular in medicine. They also occur naturally in many food products. The aim of the study was to investigate the effect of the personalized low salicylate diet (PLSD) on the reduction of asthma, rhinosinusitis and urticaria symptoms in patients with hypersensitivity to aspirin (ASA) or nonsteroidal anti-inflammatory drugs (NSAIDs). To achieve the research goal, a prospective, nonrandomized, baseline-controlled intervention study was conducted. Thirty patients diagnosed with NSAIDs hypersensitivity, who despite pharmacotherapy had symptoms of hypersensitivity, were included in the study. The PLSD was recommended for all participants for a period of two to four weeks. The intensity of subjectively declared symptoms of asthma, rhinosinusitis and urticaria were measured before and after dietary intervention, using, respectively, the asthma control test (ACT), the sino-nasal outcome test (SNOT-22) and the four-item itch questionnaire (FIIQ). Diet adherence and salicylate intake were measured by a 3-day food record. The severity of symptoms improved significantly after the intervention. The median of the ACT score was 24 scores before and 25 after the dietary intervention (p < 0.002), the median of the SNOT-22 score was 25 before and 13 after a dietary intervention (p < 0.0002) and the median of the FIIQ score was 5 before and 0 after a dietary intervention (p < 0.0002). The intake of salicylates decreased from 0.79 mg/day (before intervention) to 0.15 mg/day (p < 0.001) (during intervention). Although the usefulness of a low salicylate diet in the treatment of salicylate hypersensitivity is controversial, the results of our study indicate that the PLSD may have a positive effect in reducing symptoms of salicylate hypersensitivity and could be an additional tool supporting the therapy of these patients.
Open AccessEffectiveness of Personalized Low Salicylate Diet in the Management of Salicylates Hypersensitive Patients: Interventional Study
Salicylic acid and its derivatives (including acetylsalicylic acid/aspirin) are popular in medicine. They also occur naturally in many food products. The aim of the study was to investigate the effect of the personalized low salicylate diet (PLSD) on the reduction of asthma, rhinosinusitis and urticaria symptoms in patients with hypersensitivity to aspirin (ASA) or nonsteroidal anti-inflammatory drugs (NSAIDs). To achieve the research goal, a prospective, nonrandomized, baseline-controlled intervention study was conducted. Thirty patients diagnosed with NSAIDs hypersensitivity, who despite pharmacotherapy had symptoms of hypersensitivity, were included in the study. The PLSD was recommended for all participants for a period of two to four weeks. The intensity of subjectively declared symptoms of asthma, rhinosinusitis and urticaria were measured before and after dietary intervention, using, respectively, the asthma control test (ACT), the sino-nasal outcome test (SNOT-22) and the four-item itch questionnaire (FIIQ). Diet adherence and salicylate intake were measured by a 3-day food record. The severity of symptoms improved significantly after the intervention. The median of the ACT score was 24 scores before and 25 after the dietary intervention (p < 0.002), the median of the SNOT-22 score was 25 before and 13 after a dietary intervention (p < 0.0002) and the median of the FIIQ score was 5 before and 0 after a dietary intervention (p < 0.0002). The intake of salicylates decreased from 0.79 mg/day (before intervention) to 0.15 mg/day (p < 0.001) (during intervention). Although the usefulness of a low salicylate diet in the treatment of salicylate hypersensitivity is controversial, the results of our study indicate that the PLSD may have a positive effect in reducing symptoms of salicylate hypersensitivity and could be an additional tool supporting the therapy of these patients.